Department of Defense Pharamacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program HT9402-25-Q-9303

Solicitation HT9402-25-Q-9303 Copied Notice ID fb6a3302b5564ed38a0209c8c0711346 Copied DEPT OF DEFENSE — DEFENSE HEALTH AGENCY

SAM.gov

Posted

Jul 24, 2025

Deadline

Jun 20, 2025

Set-aside

None

NAICS

325412

PSC

6505

Summary

AI-generated · Aug 24, 2025

The Defense Health Agency is seeking quotes to establish Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program Agreements (UF ADP) for pharmaceutical agents within drug classes selected for the DoD Uniform Formulary. Quotations will support the DoD Pharmacy and Therapeutics Committee’s process to evaluate clinical and cost effectiveness and to assign formulary status and cost-sharing classifications (generic, formulary, Basic Core Formulary, Extended Core Formulary, or non-formulary). A Request for Quotation (RFQ HT9402-25-Q-9303) with appendices outlines the requirements, deadlines, and points of contact; a pre-quotation teleconference is scheduled for June 4, 2025, and responses to clinical questions must be emailed to the RFQ POC identified in the RFQ’s Part 2.3.1 by the deadline in Part 2.3.2.

The UF decision will determine which agents are placed on the UF and how they are cost-shared. The August 2025 P&T Committee meeting will review newly approved drugs, including Hemiclor (diuretics), Symbravo (migraine triptans), umeclidinium-vilanterol (COPD), ustekinumab (IL-23 biologic), and Vyvgart Hytrulo (neurological agent). Bidders should review the RFQ attachments, follow the submission instructions, participate in the pre-bid teleconference, and provide any required information and quotes in accordance with UF BPA/ADP terms.

The Department of Defense (DoD) is required by law (10 U.S.C. 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following August 2025 newly approved drugs will be reviewed: a. Hemiclor - Diuretics - NA b. Symbravo - Migraine Agents - Triptans c. umeclidinium-vilanterol - Pulmonary-2 Agents - Chronic Obstructive Pulmonary Disease d. ustekinumab - Targeted Immunomodulatory Biologics - IL-23 e. Vyvgart Hytrulo - Neurological Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-25-Q-9303. Pre-quotation teleconference is on June 4, 2025. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.

From Solicitation posted on Jul 24, 2025